The impact of the COVID-19 pandemic on medications for opioid use disorder services in the U.S. and Canada: a scoping review

References

• *Alexander, G. C., Stoller, K. B., Haffajee, R. L., & Saloner, B. (2020). An epidemic in the midst of a pandemic: Opioid use disorder and COVID-19. Annals of Internal Medicine, 173(1), 57–58. https://doi.org/10.7326/M20-1141
   PubMed Web of Science ®Google Scholar
• Amiri, S., Lutz, R., Socías, M. E., McDonell, M. G., Roll, J. M., & Amram, O. (2018). Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington. Journal of Substance Abuse Treatment, 93, 26–30. https://doi.org/10.1016/j.jsat.2018.07.006
   PubMed Web of Science ®Google Scholar
• *Andraka-Christou, B., Bouskill, K., Haffajee, R. L., Randall-Kosich, O., Golan, M., Totaram, R., Gordon, A. J., & Stein, B. D. (2021). Common themes in early state policy responses to substance use disorder treatment during COVID-19. Journal of Drug and Alcohol Abuse, 1, 1–11. https://doi.org/10.1080/00952990.2021.1903023
   Google Scholar
• Bacha, J., Reast, S., & Pearlstone, A. (2010). Treatment practices and perceived challenges for European physicians treating opioid dependence. Heroin Addiction and Related Clinical Problems, 12(3), 9–19.
   Web of Science ®Google Scholar
• *Bandara, S., Kennedy-Hendricks, A., Merritt, S., Barry, C. L., & Saloner, B. (2020). Early effects of COVID-19 on programs providing medications for opioid use disorder in jails and prisons. Journal of Addiction Medicine, 14(5), e257–e260. https://doi.org/10.1097/ADM.0000000000000718
   PubMed Web of Science ®Google Scholar
• *Banks, D. E., Carpenter, R. W., Wood, C. A., & Winograd, R. P. (2021). Commentary on Furr-Holden et al.: As opioid overdose deaths accelerate among Black Americans, COVID-19 widens inequities: A critical need to invest in community-based approaches. Addiction, 116(3), 686–687. https://doi.org/10.1111/add.15362
   PubMed Web of Science ®Google Scholar
• *Becker, S. J., Garner, B. R., & Hartzler, B. J. (2021). Is necessity also the mother of implementation? COVID-19 and the implementation of evidence-based treatments for opioid use disorders. Journal of Substance Abuse Treatment, 122, 108210. https://doi.org/10.1016/j.jsat.2020.108210
   PubMed Web of Science ®Google Scholar
• Binswanger, I. A., Stern, M. F., Deyo, R. A., Heagerty, P. J., Cheadle, A., Elmore, J. G., & Koepsell, T. D. (2007). Release from prison: A high risk of death for former inmates. The New England Journal of Medicine, 356(2), 157-165. https://doi.org/10.1056/NEJMsa064115
   Web of Science ®Google Scholar
• *Brothers, S., Viera, A., & Heimer, R. (2021). Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19. Journal of Substance Abuse Treatment, 131, 108449. https://doi.org/10.1016/j.jsat.2021.108449
   PubMed Web of Science ®Google Scholar
• *Buchheit, B. M., Wheelock, H., Lee, A., Brandt, K., & Gregg, J. (2021). Low-barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects. Journal of Substance Abuse Treatment, 131, 108444. https://doi.org/10.1016/j.jsat.2021.108444
   PubMed Web of Science ®Google Scholar
• Calcaterra, S. L., Bach, P., Chadi, A., Chadi, N., Kimmel, S. D., Morford, K. L., Roy, P., & Samet, J. H. (2019). Methadone matters: What the United States can learn from the global effort to treat opioid addiction. Journal of General Internal Medicine, 34(6), 1039–1042. https://doi.org/10.1007/s11606-018-4801-3
   PubMed Web of Science ®Google Scholar
• *Cance, J. D., & Doyle, E. (2020). Changes in outpatient buprenorphine dispensing during the COVID-19 pandemic. JAMA, 324(23), 2442–2444. https://doi.org/10.1001/jama.2020.22154
   PubMed Web of Science ®Google Scholar
• *Cantor, J., Dick, A. W., Haffajee, R., Pera, M. F., Bravata, D. M., Stein, B. D., & Whaley, C. M. (2021). Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic [Review]. Journal of Substance Abuse Treatment, 129, 108384. https://doi.org/10.1016/j.jsat.2021.108384
   PubMed Web of Science ®Google Scholar
• *Cantor, J., & Laurito, A. (2021). The new services that opioid treatment programs have adopted in response to COVID-19. Journal of Substance Abuse Treatment, 130, 108393. https://doi.org/10.1016/j.jsat.2021.108393
   PubMed Web of Science ®Google Scholar
• *Castillo, M., Conte, B., Hinkes, S., Mathew, M., Na, C. J., Norindr, A., Serota, D. P., Forrest, D. W., Deshpande, A. R., Bartholomew, T. S., & Tookes, H. E. (2020). Implementation of a medical student-run telemedicine program for medications for opioid use disorder during the COVID-19 pandemic. Harm Reduction Journal, 17(1), 88. https://doi.org/10.1186/s12954-020-00438-4
   PubMed Web of Science ®Google Scholar
• *Caton, L., Cheng, H., Garneau, H. C., Fisher, T., Harris-Mills, B., Hurley, B., Newman, S., & McGovern, M. P. (2021). COVID-19 adaptations in the care of patients with opioid use disorder: A survey of California primary care clinics. Journal of General Internal Medicine, 36(4), 998–1005. https://doi.org/10.1007/s11606-020-06436-3
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. (2021, March 3). Drug overdose deaths. https://www.cdc.gov/drugoverdose/data/statedeaths.html
   Google Scholar
• Centers for Disease Control and Prevention. (2022, July 13). Provisional drug overdose death counts. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
   Google Scholar
• Centre for Addiction and Mental Health. (2020, March 22). COVID-19 opioid agonist treatment guidance. https://www.camh.ca/-/media/files/covid-19-modifications-to-opioid-agonist-treatment-delivery-pdf.pdf
   Google Scholar
• *Clark, S. A., Davis, C., Wightman, R. S., Wunsch, C., Keeler, L. A. J., Reddy, N., & Samuels, E. A. (2021). Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island. Journal of Substance Abuse Treatment, 124, 108283. https://doi.org/10.1016/j.jsat.2021.108283
   PubMed Web of Science ®Google Scholar
• *Collins, A. B., Beaudoin, F. L., Samuels, E. A., Wightman, R., & Baird, J. (2021). The impact of COVID-19 on service provision for emergency department patients post-opioid overdose: A field report. Journal of Addiction Medicine, 15(5), 432–434. https://doi.org/10.1097/ADM.0000000000000779
   PubMed Web of Science ®Google Scholar
• Connery, H. S. (2015). Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. Harvard Review of Psychiatry, 23(2), 63–75. https://doi.org/10.1097/HRP.0000000000000075
   PubMed Web of Science ®Google Scholar
• Davis, C. S., & Carr, D. H. (2019). Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States. International Journal of Drug Policy, 73, 42–48. https://doi.org/10.1016/j.drugpo.2019.07.006
   PubMed Web of Science ®Google Scholar
• *Davis, C. S., & Samuels, E. A. (2020). Opioid policy changes during the COVID-19 pandemic—and beyond. Journal of Addiction Medicine, 14(4), e4–e5. https://doi.org/10.1097/ADM.0000000000000679
   PubMed Web of Science ®Google Scholar
• *Del Pozo, B., Beletsky, L., & Rich, J. D. (2020). COVID-19 as a frying pan: The promise and perils of pandemic-driven reform. Journal of Addiction Medicine, 14(5), e144–e146. https://doi.org/10.1097/ADM.0000000000000703
   PubMed Web of Science ®Google Scholar
• *Donelan, C. J., Hayes, E., Potee, R. A., Schwartz, L., & Evans, E. A. (2021). COVID-19 and treating incarcerated populations for opioid use disorder. Journal of Substance Abuse Treatment, 124, 108216. https://doi.org/10.1016/j.jsat.2020.108216
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration. (2020, Mar 31). Letter to DEA qualifying practitioners. https://www.deadiversion.usdoj.gov/GDP/(DEA-DC-022)(DEA068)%20DEA%20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf
   Google Scholar
• *Duncan, A., Sanders, N., Schiff, M., & Winkelman, T. N. A. (2021). Adaptations to jail-based buprenorphine treatment during the COVID-19 pandemic. Journal of Substance Abuse Treatment, 121, 108161. https://doi.org/10.1016/j.jsat.2020.108161
   PubMed Web of Science ®Google Scholar
• *Figgatt, M. C., Salazar, Z., Day, E., Vincent, L., & Dasgupta, N. (2021). Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. Journal of Substance Abuse Treatment, 123, 108276. https://doi.org/10.1016/j.jsat.2021.108276
   PubMed Web of Science ®Google Scholar
• Fullerton, C. A., Kim, M., Thomas, C. P., Lyman, D. R., Montejano, L. B., Dougherty, R. H., Daniels, A. S., Ghose, S. S., & Delphin-Rittmon, M. E. (2014). Medication-assisted treatment with methadone: Assessing the evidence. Psychiatric Services, 65(2), 146–157. https://doi.org/10.1176/appi.ps.201300235
   PubMed Web of Science ®Google Scholar
• *Gleason, E., Nolan, N. S., Marks, L. R., Habrock, T., Liang, S. Y., & Durkin, M. J. (2021). Barriers to care experienced by patients who inject drugs during the COVID-19 pandemic: A qualitative analysis. Journal of Addiction Medicine, 16(2), e133. https://doi.org/10.1097/ADM.0000000000000853
   Google Scholar
• *Gustavson, A. M., Gordon, A. J., Kenny, M. E., McHenry, H., Gronek, J., Ackland, P. E., & Hagedorn, H. J. (2020). Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder. Substance Abuse, 41(4), 413–418. https://doi.org/10.1080/08897077.2020.1809609
   PubMed Web of Science ®Google Scholar
• Haffajee, R. L., Lin, L. A., Bohnert, A. S., & Goldstick, J. E. (2019). Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. JAMA Network Open, 2(6), e196373. https://doi.org/10.1001/jamanetworkopen.2019.6373
   PubMed Web of Science ®Google Scholar
• *Harris, M., Johnson, S., Mackin, S., Saitz, R., Walley, A. Y., & Taylor, J. L. (2020). Low barrier tele-buprenorphine in the time of COVID-19: A case report. Journal of Addiction Medicine, 14(4), e136–e138. https://doi.org/10.1097/ADM.0000000000000682
   PubMed Web of Science ®Google Scholar
• *Herring, A. A., Kalmin, M., Speener, M., Goodman-Meza, D., Snyder, H., Campbell, A., Moulin, A., & Shoptaw, S. (2021). Sharp decline in hospital and emergency department initiated buprenorphine for opioid use disorder during COVID-19 state of emergency in California. Journal of Substance Abuse Treatment, 123, 108260. https://doi.org/10.1016/j.jsat.2020.108260
   PubMed Web of Science ®Google Scholar
• *Hser, Y.-I., Ober, A. J., Dopp, A. R., Lin, C., Osterhage, K. P., Clingan, S. E., Mooney, L. J., Curtis, M. E., Marsch, L. A., McLeman, B., Hichborn, E., Lester, L. S., Baldwin, L.-M., Liu, Y., Jacobs, P., & Saxon, A. J. (2021). Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial. Addiction Science & Clinical Practice, 16(1), 24. https://doi.org/10.1186/s13722-021-00233-x
   PubMed Web of Science ®Google Scholar
• *Hughes, P. M., Verrastro, G., Fusco, C. W., Wilson, C. G., & Ostrach, B. (2021). An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic. The Journal of Rural Health, 37(3), 467–472. https://doi.org/10.1111/jrh.12570
   PubMed Web of Science ®Google Scholar
• *Hunter, S. B., Dopp, A. R., Ober, A. J., & Uscher-Pines, L. (2021). Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: A qualitative study. Journal of Substance Abuse Treatment, 124, 108288. https://doi.org/10.1016/j.jsat.2021.108288
   PubMed Web of Science ®Google Scholar
• *Huskamp, H. A., Busch, A. B., Uscher-Pines, L., Barnett, M. L., Riedel, L., & Mehrotra, A. (2020). Treatment of opioid use disorder among commercially insured patients in the context of the COVID-19 pandemic. JAMA, 324(23), 2440–2442. https://doi.org/10.1001/jama.2020.21512
   PubMed Web of Science ®Google Scholar
• *Ivey, N., & Clifton, D. C. (2021). Tales from the frontlines: An alarming rise in hospitalizations related to opioid use disorder in the era of COVID-19. Journal of Opioid Management, 17(1), 5–7. https://doi.org/10.5055/jom.2021.0608
   PubMedGoogle Scholar
• *Jones, C. M., Diallo, M. M., Vythilingam, M., Schier, J. G., Eisenstat, M., & Compton, W. M. (2021). Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic. Drug and Alcohol Dependence, 225, 108783. https://doi.org/10.1016/j.drugalcdep.2021.108783
   PubMed Web of Science ®Google Scholar
• *Joseph, G., Torres-Lockhart, K., Stein, M. R., Mund, P. A., & Nahvi, S. (2021). Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19. Journal of Substance Abuse Treatment, 122, 108219. https://doi.org/10.1016/j.jsat.2020.108219
   PubMed Web of Science ®Google Scholar
• *Kelley, A. T., Dungan, M. T., & Gordon, A. J. (2021). Barriers and facilitators to buprenorphine prescribing for opioid use disorder in the Veterans Health Administration during COVID-19. Journal of Addiction Medicine, 15(5), 439–440. https://doi.org/10.1097/ADM.0000000000000786
   PubMed Web of Science ®Google Scholar
• Korthuis, P. T., McCarty, D., Weimer, M., Bougatsos, C., Blazina, I., Zakher, B., Grusing, S., Devine, B., & Chou, R. (2017). Primary care–based models for the treatment of opioid use disorder: A scoping review. Annals of Internal Medicine, 166(4), 268–278. https://doi.org/10.7326/M16-2149
   PubMed Web of Science ®Google Scholar
• *Krawczyk, N., Fingerhood, M. I., & Agus, D. (2020). Lessons from COVID 19: Are we finally ready to make opioid treatment accessible? Journal of Substance Abuse Treatment, 117, 108074. https://doi.org/10.1016/j.jsat.2020.108074
   PubMed Web of Science ®Google Scholar
• Krawczyk, N., Picher, C. E., Feder, K. A., & Saloner, B. (2017). Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Affairs (Project Hope), 36(12), 2046–2053. https://doi.org/10.1377/hlthaff.2017.0890
   PubMed Web of Science ®Google Scholar
• Kruse, C. S., Krowski, N., Rodriguez, B., Tran, L., Vela, J., & Brooks, M. (2017). Telehealth and patient satisfaction: A systematic review and narrative analysis. BMJ Open, 7(8), e016242. https://doi.org/10.1136/bmjopen-2017-016242
   PubMed Web of Science ®Google Scholar
• Lagisetty, P. A., Ross, R., Bohnert, A., Clay, M., & Maust, D. T. (2019). Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry, 76(9), 979–981. https://doi.org/10.1001/jamapsychiatry.2019.0876
   PubMed Web of Science ®Google Scholar
• *Langabeer, J. R., Yatsco, A., & Champagne-Langabeer, T. (2021). Telehealth sustains patient engagement in OUD treatment during COVID-19. Journal of Substance Abuse Treatment, 122, 108215. https://doi.org/10.1016/j.jsat.2020.108215
   PubMed Web of Science ®Google Scholar
• *Leo, P., Gastala, N., Fleurimont, J., Messmer, S., Maes, P., Richardson, J., Neeb, C., Stackhouse, N., Koruba, S., & Watson, D. P. (2021). A community partnership to improve access to buprenorphine in a homeless population. Annals of Family Medicine, 19(1), 85. https://doi.org/10.1370/afm.2636
   PubMed Web of Science ®Google Scholar
• Lima, N. N. R., de Souza, R. I., Feitosa, P. W. G., Moreira, J. L. d S., da Silva, C. G. L., & Neto, M. L. R. (2020). People experiencing homelessness: Their potential exposure to COVID-19. Psychiatry Research, 288, 112945. https://doi.org/10.1016/j.psychres.2020.112945
   PubMed Web of Science ®Google Scholar
• Lin, C. C. C., Dievler, A., Robbins, C., Sripipatana, A., Quinn, M., & Nair, S. (2018). Telehealth in health centers: Key adoption factors, barriers, and opportunities. Health Affairs (Project Hope), 37(12), 1967–1974. https://doi.org/10.1377/hlthaff.2018.05125
   PubMed Web of Science ®Google Scholar
• *MacKinnon, L., Socias, M. E., & Bardwell, G. (2020). COVID-19 and overdose prevention: Challenges and opportunities for clinical practice in housing settings. Journal of Substance Abuse Treatment, 119, 108153. https://doi.org/10.1016/j.jsat.2020.108153
   PubMed Web of Science ®Google Scholar
• Mancher, M., & Leshner, A. I. (2019). Medications for opioid use disorder in various treatment settings. In A. I. Leshner & M. Mancher (Eds.), Medications for opioid use disorder save lives (pp. 91–108). National Academies Press. https://doi.org/10.17226/25310
   Google Scholar
• *McIlveen, J. W., Hoffman, K., Priest, K. C., Choi, D., Korthuis, P. T., & McCarty, D. (2021). Reduction in Oregon’s medication dosing visits after the SARS-CoV-2 relaxation of restrictions on take-home medication. Journal of Addiction Medicine, 15(6), 516–518. https://doi.org/10.1097/ADM.0000000000000812
   PubMed Web of Science ®Google Scholar
• *McLaughlin, M. F., Li, R., Carrero, N. D., Bain, P. A., & Chatterjee, A. (2021). Opioid use disorder treatment for people experiencing homelessness: A scoping review. Drug and Alcohol Dependence, 224, 108717. https://doi.org/10.1016/j.drugalcdep.2021.108717
   PubMed Web of Science ®Google Scholar
• *Mehtani, N. J., Ristau, J. T., Snyder, H., Surlyn, C., Eveland, J., Smith-Bernardin, S., & Knight, K. R. (2021). COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management. Substance Abuse, 42(2), 205–212. https://doi.org/10.1080/08897077.2021.1890676
   PubMed Web of Science ®Google Scholar
• *Mistler, C. B., Sullivan, M. C., Copenhaver, M. M., Meyer, J. P., Roth, A. M., Shenoi, S. V., Edelman, E. J., Wickersham, J. A., & Shrestha, R. (2021). Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder. Journal of Substance Abuse Treatment, 129, 108387. https://doi.org/10.1016/j.jsat.2021.108387
   PubMed Web of Science ®Google Scholar
• *Mitchell, M., Shee, K., Champlin, K., Essary, A. C., & Evans, M. (2021). Opioid use disorder and COVID-19: Implications for policy and practice. Journal of the American Academy of Physician Assistants, 34(6), 1–4. https://doi.org/10.1097/01.JAA.0000742976.14811.36
   Google Scholar
• *Molfenter, T., Roget, N., Chaple, M., Behlman, S., Cody, O., Hartzler, B., Johnson, E., Nichols, M., Stilen, P., & Becker, S. (2021). Use of telehealth in substance use disorder services during and after COVID-19: Online survey study. JMIR Mental Health, 8(2), e25835. https://doi.org/10.2196/25835
   PubMed Web of Science ®Google Scholar
• *Morin, K. A., Acharya, S., Eibl, J. K., & Marsh, D. C. (2021). Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada. The International Journal on Drug Policy, 90, 103088. https://doi.org/10.1016/j.drugpo.2020.103088
   PubMed Web of Science ®Google Scholar
• *Nguemeni Tiako, M. J. (2021). Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19. Journal of Substance Abuse Treatment, 122, 108214. https://doi.org/10.1016/j.jsat.2020.108214
   PubMed Web of Science ®Google Scholar
• *Nguyen, T. D., Saloner, B., & Stein, B. D. (2021). Buprenorphine opioid treatment during the COVID-19 pandemic-reply. JAMA Internal Medicine, 181(8), 1135–1136. https://doi.org/10.1001/jamainternmed.2021.0774
   PubMed Web of Science ®Google Scholar
• *Nordeck, C. D., Buresh, M., Krawczyk, N., Fingerhood, M., & Agus, D. (2021). Adapting a low-threshold buprenorphine program for vulnerable populations during the COVID-19 pandemic. Journal of Addiction Medicine, 15(5), 364–369. https://doi.org/10.1097/ADM.0000000000000774
   PubMed Web of Science ®Google Scholar
• *Noyes, E., Yeo, E., Yerton, M., Plakas, I., Keyes, S., Obando, A., Gaeta, J. M., Taveras, E. M., & Chatterjee, A. (2021). Harm reduction for adolescents and young adults during the COVID-19 pandemic: A case study of community care in reach. Public Health Reports, 136(3), 301–308. https://doi.org/10.1177/0033354921999396
   PubMed Web of Science ®Google Scholar
• Palombi, L. C., St Hill, C. A., Lipsky, M. S., Swanoski, M. T., & Lutfiyya, M. N. (2018). A scoping review of opioid misuse in the rural United States. Annals of Epidemiology, 28(9), 641–652. https://doi.org/10.1016/j.annepidem.2018.05.008
   PubMed Web of Science ®Google Scholar
• *Peavy, K. M., Darnton, J., Grekin, P., Russo, M., Green, C. J. B., Merrill, J. O., Fotinos, C., Woolworth, S., Soth, S., & Tsui, J. I. (2020). Rapid implementation of service delivery changes to mitigate COVID-19 and maintain access to methadone among persons with and at high-risk for HIV in an opioid treatment program. AIDS and Behavior, 24(9), 2469–2472. https://doi.org/10.1007/s10461-020-02887-1
   PubMed Web of Science ®Google Scholar
• *Pena, E., & Ahmed, S. (2020). Time to revisit uneven policy in the United States for medication for opioid use disorder during COVID-19. Addiction, 115(10), 1978–1979. https://doi.org/10.1111/add.15143
   PubMed Web of Science ®Google Scholar
• *Peterkin, A., Davis, C. S., & Weinstein, Z. (2022 Mar-Apr 01). Permanent methadone treatment reform needed to combat the opioid crisis and structural racism. Journal of Addiction Medicine, 16(2), 127–129. https://doi.org/10.1097/ADM.0000000000000841
   PubMed Web of Science ®Google Scholar
• Peters, M. D. J., Godfrey, C. M., Khalil, H., McInerney, P., Parker, D., & Soares, C. B. (2015). Guidance for conducting systematic scoping reviews. International Journal of Evidence-Based Healthcare, 13(3), 141–146. https://doi.org/10.1097/XEB.0000000000000050
   PubMed Web of Science ®Google Scholar
• Priest, K. C., Gorfinkel, L., Klimas, J., Jones, A. A., Fairbairn, N., & McCarty, D. (2019). Comparing Canadian and United States opioid agonist therapy policies. The International Journal on Drug Policy, 74, 257–265. https://doi.org/10.1016/j.drugpo.2019.01.020
   PubMed Web of Science ®Google Scholar
• *Pytell, J. D., & Rastegar, D. A. (2021). Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic. Journal of Substance Abuse Treatment, 120, 108155. https://doi.org/10.1016/j.jsat.2020.108155
   PubMed Web of Science ®Google Scholar
• Richard, E. L., Schalkoff, C. A., Piscalko, H. M., Brook, D. L., Sibley, A. L., Lancaster, K. E., Miller, W. C., & Go, V. F. (2020). “You are not clean until you’re not on anything”: Perceptions of medication-assisted treatment in rural Appalachia. International Journal of Drug Policy, 85, 102704. https://doi.org/10.1016/j.drugpo.2020.102704
   PubMed Web of Science ®Google Scholar
• Rieckmann, T., Moore, L. A., Croy, C. D., Novins, D. K., & Aarons, G. (2016). A national study of American Indian and Alaska Native substance abuse treatment: Provider and program characteristics. Journal of Substance Abuse Treatment, 68, 46–56. https://doi.org/10.1016/j.jsat.2016.05.007
   PubMed Web of Science ®Google Scholar
• Roehler, D. R., Guy, G. P., & Jones, C. M. (2020). Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: A cross-sectional study. Drug and Alcohol Dependence, 213, 108083. https://doi.org/10.1016/j.drugalcdep.2020.108083
   PubMed Web of Science ®Google Scholar
• Roman, P. M., Abraham, A. J., & Knudsen, H. K. (2011). Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation. Addictive Behaviors, 36(6), 584–589. https://doi.org/10.1016/j.addbeh.2011.01.032
   PubMed Web of Science ®Google Scholar
• *Russell, C., Ali, F., Nafeh, F., Rehm, J., LeBlanc, S., & Elton-Marshall, T. (2021). Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study. Journal of Substance Abuse Treatment, 129, 108374. https://doi.org/10.1016/j.jsat.2021.108374
   PubMed Web of Science ®Google Scholar
• *Samuels, E. A., Clark, S. A., Wunsch, C., Jordison Keeler, L. A., Reddy, N., Vanjani, R., & Wightman, R. S. (2020). Innovation during COVID-19: Improving addiction treatment access. Journal of Addiction Medicine, 14(4), e8–e9. https://doi.org/10.1097/ADM.0000000000000685
   PubMed Web of Science ®Google Scholar
• *Sokol, R., Suter, S., Pierce, B., Council, L., Grossman, E., Roland, L., Roll, D., & Mintzer, E. (2021). A novel transition: Lessons learned during rapid implementation and evolution of telehealth group based opioid treatment (t-GBOT) during the COVID-19 pandemic. Healthcare, 9(3), 100559. https://doi.org/10.1016/j.hjdsi.2021.100559
   Web of Science ®Google Scholar
• Special Advisory Committee on the Epidemic of Opioid Overdoses. (2021, June 23) Opioid- and stimulant-related harms in Canada. https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/
   Google Scholar
• Special Advisory Committee on the Epidemic of Opioid Overdoses. (2022, June 23) Opioid- and stimulant-related harms in Canada. https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/
   Google Scholar
• Stevens-Watkins, D. (2020). Opioid-related overdose deaths among African Americans: Implications for research, practice and policy. Drug and Alcohol Review, 39(7), 857–861. https://doi.org/10.1111/dar.13058
   PubMed Web of Science ®Google Scholar
• *Stringer, K. L., Langdon, K. J., McKenzie, M., Brockmann, B., & Marotta, P. (2021). Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder. Journal of Substance Abuse Treatment, 123, 108263. https://doi.org/10.1016/j.jsat.2020.108263
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. (2015, January). Federal Guidelines for opioid treatment programs. https://store.samhsa.gov/sites/default/files/d7/priv/pep15-fedguideotp.pdf
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2019, August). Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHNationalFindingsReport2018/NSDUHNationalFindingsReport2018.pdf
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2020a, March 16). Opioid treatment program (OTP) guidance. https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2020b, March 30). OTP guidance for patients quarantined at home with the coronavirus. https://www.samhsa.gov/sites/default/files/otp-covid-implementation-guidance.pdf
   Google Scholar
• Thomas, C. P., Fullerton, C. A., Kim, M., Montejano, L., Lyman, D. R., Dougherty, R. H., Daniels, A. S., Ghose, S. S., & Delphin-Rittmon, M. E. (2014). Medication-assisted treatment with buprenorphine: Assessing the evidence. Psychiatric Services, 65(2), 158–170. https://doi.org/10.1176/appi.ps.201300256
   PubMed Web of Science ®Google Scholar
• *Thornton, J. D., Varisco, T. J., Bapat, S. S., Downs, C. G., & Shen, C. (2020). Impact of COVID-19 related policy changes on buprenorphine dispensing in Texas. Journal of Addiction Medicine, 14(6), e372–e374. https://doi.org/10.1097/ADM.0000000000000756
   PubMed Web of Science ®Google Scholar
• *Tofighi, B., McNeely, J., Walzer, D., Fansiwala, K., Demner, A., Chaudhury, C. S., Subudhi, I., Schatz, D., Reed, T., & Krawczyk, N. (2022). A telemedicine buprenorphine clinic to serve New York City: Initial evaluation of the NYC public hospital system’s initiative to expand treatment access during the COVID-19 pandemic. Journal of Addiction Medicine, 16(1), e40–e43. https://doi.org/10.1097/ADM.0000000000000809
   PubMed Web of Science ®Google Scholar
• *Tracy, K., Wachtel, L., & Friedman, T. (2021). The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here? [Review]. Journal of Substance Abuse Treatment, 131, 108394. https://doi.org/10.1016/j.jsat.2021.108394
   PubMed Web of Science ®Google Scholar
• *Treitler, P. C., Bowden, C. F., Lloyd, J., Enich, M., Nyaku, A. N., & Crystal, S. (2022). Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms. Journal of Substance Abuse Treatment, 132, 108514. https://doi.org/10.1016/j.jsat.2021.108514
   PubMed Web of Science ®Google Scholar
• Tricco, A. C., Lillie, E., Zarin, W., O’Brien, K., Colquhoun, H., Kastner, M., Levac, D., Ng, C., Sharpe, J. P., Wilson, K., Kenny, M., Warren, R., Wilson, C., Stelfox, H. T., & Straus, S. E. (2016). A scoping review on the conduct and reporting of scoping reviews. BMC Medical Research Methodology, 16(1), 15. https://doi.org/10.1186/s12874-016-0116-4
   PubMed Web of Science ®Google Scholar
• *Uscher-Pines, L., Sousa, J., Raja, P., Mehrotra, A., Barnett, M., & Huskamp, H. A. (2020). Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine. Journal of Substance Abuse Treatment, 118, 108124. https://doi.org/10.1016/j.jsat.2020.108124
   PubMed Web of Science ®Google Scholar
• Venner, K. L., Donovan, D. M., Campbell, A. N. C., Wendt, D. C., Rieckmann, T., Radin, S. M., Momper, S. L., & Rosa, C. L. (2018). Future directions for medication assisted treatment for opioid use disorder with American Indian/Alaska Natives. Addictive Behaviors, 86, 111–117. https://doi.org/10.1016/j.addbeh.2018.05.017
   PubMed Web of Science ®Google Scholar
• *Wang, L., Weiss, J., Ryan, E. B., Waldman, J., Rubin, S., & Griffin, J. L. (2021). Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic. Journal of Substance Abuse Treatment, 124, 108272. https://doi.org/10.1016/j.jsat.2020.108272
   PubMed Web of Science ®Google Scholar
• *Wang, Q. Q., Kaelber, D. C., Xu, R., & Volkow, N. D. (2021). COVID-19 risk and outcomes in patients with substance use disorders: Analyses from electronic health records in the United States. Molecular Psychiatry, 26(1), 30–39. https://doi.org/10.1038/s41380-020-00880-7
   PubMed Web of Science ®Google Scholar
• Webb Hooper, M., Nápoles, A. M., & Pérez-Stable, E. J. (2020). COVID-19 and racial/ethnic disparities. JAMA, 323(24), 2466–2467. https://doi.org/10.1001/jama.2020.8598
   PubMed Web of Science ®Google Scholar
• Weiss, R. D., Jaffee, W. B., de Menil, V. P., & Cogley, C. B. (2004). Group therapy for substance use disorders: What do we know? Harvard Review of Psychiatry, 12(6), 339–350. https://doi.org/10.1080/10673220490905723
   PubMed Web of Science ®Google Scholar
• *Wendt, D. C., Marsan, S., Parker, D., Lizzy, K. E., Roper, J., Mushquash, C., Venner, K. L., Lam, A., Swansburg, J., Worth, N., Sorlagas, N., Quach, T., Manoukian, K., Bernett, P., & Radin, S. M. (2021). Commentary on the impact of the COVID-19 pandemic on opioid use disorder treatment among Indigenous communities in the United States and Canada. Journal of Substance Abuse Treatment, 121, 108165. https://doi.org/10.1016/j.jsat.2020.108165
   PubMed Web of Science ®Google Scholar
• *Wenzel, K., & Fishman, M. (2021). Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency. Journal of Substance Abuse Treatment, 120, 108149. https://doi.org/10.1016/j.jsat.2020.108149
   PubMed Web of Science ®Google Scholar
• Wilson, N., Kariisa, M., Seth, P., Smith, I. V.H., & Davis, N. L. (2020). Drug and opioid-involved overdose deaths—United States, 2017–2018. Morbidity and Mortality Weekly Report, 69(11), 290. https://doi.org/10.15585/mmwr.mm6911a4
   PubMed Web of Science ®Google Scholar
• Wood, E., Montaner, J. S., Li, K., Barney, L., Tyndall, M. W., & Kerr, T. (2007). Rate of methadone use among Aboriginal opioid injection drug users. Canadian Medical Association Journal, 177(1), 37–40. https://doi.org/10.1503/cmaj.070105
   Web of Science ®Google Scholar
• Yamamoto, A., Needleman, J., Gelberg, L., Kominski, G., Shoptaw, S., & Tsugawa, Y. (2019). Association between homelessness and opioid overdose and opioid-related hospital admissions/emergency department visits. Social Science & Medicine, 242, 112585. https://doi.org/10.1016/j.socscimed.2019.112585
   PubMed Web of Science ®Google Scholar